The world's largest, most comprehensive CRO, powered by Healthcare Intelligence.
Dr. Steve Cutler, CEO
JP Morgan Healthcare Conference
January 12, 2022
Forward Looking Statements
Certain statements will be forward looking statements. Actual results may differ materially from those stated or implied by forward looking statements due to economic and industry conditions and risks and uncertainties associated with the
company's business. Listeners are cautioned that
forward looking statements are not guarantees of future performance. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. Certain of the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F, filed February 24, 2021, discuss the risks and uncertainties associated with the company's business.
This presentation includes selected non-GAAP financial measures.
While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, we believe certain non-GAAP information is more useful to investors for historical comparison purposes. For a presentation of the most directly comparable GAAP financial measures, please refer to the latest Form 6-K (Unaudited) filed with the Securities and Exchange Commission.
2
What we do
ICON is a global provider of clinical development services, specializing in the strategic development, management and analysis of programs that support Clinical Development Phase I-IV clinical studies.
3
3
Our
Purpose
Our Strategic Focus
Our Foundations
Mission: To improve the lives of patients by accelerating the development
of our customers' drugs and devices through innovative solutions.
Vision: To be the healthcare intelligence partner of choice by delivering
industry leading solutions and best in class performance in clinical development.
Patient
Career
Enduring
Healthcare
Development
Intelligence
Access &
Customer
& Employer
& Applied
Engagement
Partnerships
of choice
Innovation
Operational Excellence, Quality & Delivery
Ownit@ICON: Collaboration, Agility, Integrity and Inclusion
4
A story of growth.
From a small team of 5 people in 1990, ICON now employs over 38,000 people across 159 offices in 53 countries.* We've experienced year-on-year organic growth, bolstered through a number of strategic acquisitions which have broadened, or added scale to, our service portfolio.
*as at 30 Sept 2021
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
ICON plc published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 12:35:05 UTC.
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
ICON PUBLIC LIMITED COMPANY 
